Table 1 A summary of the unique genetic events associated with the chemotherapy curable malignancies

Trophoblast tumours

Post Mole GTT

Nuclear Fusion

100%

Methotrexate or Dactinomycin

[29]

Gestational choriocarcinoma

Nuclear Fusion

95%

Etoposide, Methotrexate Dactinomycin, Cyclophosphamide, Vincristine

[30]

PSTT

Nuclear Fusion

49%

Etoposide, Methotrexate Dactinomycin, Etoposide, Cisplatin

[31]

Germ cell tumours

Testicular cancer

Meiosis

90%

Bleomycin, Etoposide, Cisplatin

[32]

Ovarian germ cell tumour

Meiosis

81%

Bleomycin, Etoposide, Cisplatin

[33]

Childhood malignancies

Wilms

Gastrulation

80%

Dactinomycin, Vincristine, Doxorubicin

[34]

Neuroblastoma

Gastrulation

40–90%

Carboplatin, Etoposide, Cyclophosphamide, Doxorubicin

[35]

Ewings

Gastrulation

30%

Vincristine, Doxorubicin, Ifosfamide, Etoposide Busulphan Melphalan

[36]

Acute leukemia

B ALL

VDJ rearrangement

Child 85%

Dexamethasone, Vincristine, Asparaginase Daunorubicin

[37,38]

Adult 53%

T ALL

VDJ rearrangement

Child 75%

Dexamethasone, Vincristine, Asparaginase Daunorubicin

[39]

AML

VDJ rearrangement

40%

Daunorubicin, Cytarabine

[40]

B Cell malignancies

Hodgkin’s lymphoma

Somatic Hypermutation

80%

Doxorubicin, Bleomycin Vinblastine Dacarbazine

[41]

Diffuse large B cell lymphoma

Somatic Hypermutation

75% (GCB)

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab

[42]

40% (ABC)

Burkitt’s lymphoma

Somatic Hypermutation

80%

Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Ifosfamide

[43]

Etoposide, Cytarabine

T Cell malignancies

ALK + ve anaplastic large cell lymphoma

V(D)J rearrangement

80%

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

[44]